You are here

  • Home
  • Archive
  • Volume 83, Issue 9
  • Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Citation Tools

Article menu
Treatment
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hernández-Cruz B, Otero-Varela L, Freire-González M BIOBADASER Study Group, et al
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry
Annals of the Rheumatic Diseases 2024;83:1189-1199.